Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.

The EMA pauses all clinical studies of Sarepta and Roche's Elevidys following the reported death of a treated patient ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...

Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...

Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and ...

Recent developments in the health sector include Indian pharmaceutical stocks' dip due to tariff threats, mass FDA layoffs ...

Beijing Tsingke Biotech Co., Ltd. officially announced the appointment of Dr. Yaning Wang, a former senior expert at the FDA, ...

The top vaccine regulator ousted by Robert F. Kennedy Jr said the health secretary’s team has sought non-existent data to ...

Global health company The Cigna Group will release its first quarter 2025 financial results on Friday, May 2, 2025, and will host a conference call the same ...

The firm said the clinical trial pause is temporary as an independent data monitoring committee finalizes its analysis for submission to regulators.